Literature DB >> 28488551

[Emergency laparotomy in a trauma patient].

F Hietbrink1, R K J Simmermacher, M B de Vries, K J P van Wessem, M B de Jong, L P H Leenen.   

Abstract

- Emergency laparotomy in trauma patients can be part of the resuscitation process, is based on damage control principles and is therefore fundamentally different from elective laparotomy, for example in case of malignancies. - Indications for emergency laparotomy after trauma are based on haemodynamic instability of the patient and the procedure is focused on restoring the patient's physiological condition.- Haemodynamic and biochemical parameters are used to determine the rest of the strategy. In order to optimize the procedure, the entire treatment team should be practiced in this.- Fewer and fewer surgeons are carrying out general laparotomies and even fewer are carrying out emergency laparotomies after trauma.- Knowledge and skills about emergency laparotomy after trauma are at risk of disappearing because of this, not only for surgeons but also for other team members.- Increased centralisation, team training, more cooperation and consultation for specific indications may all contribute to expertise preservation.

Entities:  

Mesh:

Year:  2017        PMID: 28488551

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  2 in total

1.  Outcome of trauma-related emergency laparotomies, in an era of far-reaching specialization.

Authors:  Falco Hietbrink; Diederik Smeeing; Steffi Karhof; Henk Formijne Jonkers; Marijn Houwert; Karlijn van Wessem; Rogier Simmermacher; Geertje Govaert; Miriam de Jong; Ivar de Bruin; Luke Leenen
Journal:  World J Emerg Surg       Date:  2019-08-14       Impact factor: 5.469

Review 2.  The evolution of trauma care in the Netherlands over 20 years.

Authors:  Falco Hietbrink; Roderick M Houwert; Karlijn J P van Wessem; Rogier K J Simmermacher; Geertje A M Govaert; Mirjam B de Jong; Ivar G J de Bruin; Johan de Graaf; Loek P H Leenen
Journal:  Eur J Trauma Emerg Surg       Date:  2019-11-23       Impact factor: 3.693

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.